Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | FURIN | P09958 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027693 | 0.92 | PARP10 (0.64) | PARP10EPHX2MAP4K4SENP8SENP6 | |
| SCHEMBL11758749 | 0.91 | PARP10 (0.62) | PARP10EPHX2SENP8SENP6ALDH1A1 | |
| SCHEMBL3671492 | 0.90 | DGAT1 (0.49) | PARP10EPHX2MAP4K4SENP8SENP6 | |
| SCHEMBL10188577 | 0.88 | PARP10 (0.47) | PARP10EPHX2MAP4K4SENP8SENP6 | |
| SCHEMBL197827 | 0.88 | PARP10 (0.50) | PARP10EPHX2SENP8SENP6ALDH1A1 | |
| SCHEMBL601886 | 0.86 | PARP10 (0.45) | PARP10EPHX2ALDH1A1FAAH | |
| SCHEMBL601885 | 0.86 | PARP10 (0.45) | PARP10EPHX2ALDH1A1FAAH | |
| SCHEMBL9805576 | 0.83 | ALDH1A1 (0.47) | PARP10EPHX2ALDH1A1LMNA | |
| SCHEMBL1977190 | 0.82 | ALDH1A1 (0.70) | PARP10EPHX2MAP4K4SENP8SENP6 | |
| SCHEMBL28687531 | 0.81 | PDE4D (0.44) | PARP10SENP8SENP6ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | PARP10 2557/4885EPHX2 4388/4885MAP4K4 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.